



Remarks to the Author: 
Cassidy-LD,... …Narita-M, Temporal inhibition of autophagy reveals segmental reversal of aging 
with increased cancer risk 
 
Submitted to Nature Communications 
 
 
In this manuscript, Narita and colleagues investigate the link between autophagy inhibition and 
premature aging (following up, from an opposite entry point, on previous work in the field on 
mTOR inhibition, leading to enhanced autophagy), and its association with prolonged lifespan. 
Conversely, the authors find restoration of autophagy to result in partial recovery of age-
associated phenotypes, but being associated with an increased rate of tumor formation. The 
authors conclude that the preceding inhibition of autophagy determined the elevated cancer risk 
(but did not test whether hyperactivation of autophagy from normal baseline level would also 
result in higher cancer incidence). 
 
While the concept of this manuscript is not entirely novel, it provides – based on an elegant 
technical approach – important insights into autophagy-related aging mechanisms, their 
therapeutic implications (although one would have liked to see pharmacological data using 
Bafilomycin, Rapamycin and AMPK modulators to match and validate a purely gene-engineered 
model system in a more translational fashion) and surprising effects in terms of tumorigenesis. 
However, several fundamental concerns and specific questions remain before publication in Nature 
Communications should be considered. 
 
 
Major concerns and comments 
 
1. Potentially, the entire investigation might be flawed by a direct interference of the autophagic 
process with the drug metabolism of Doxycycline, either directly (ribosomal binding) or via an 
indirect metabolizing process (e.g. glucuronidation). Since no alternatively inducible shATG5 allele 
can be generated within reasonable time and effort, the authors need to provide evidence that 
steady-state/trough serum levels of Dox and typical direct Dox target pathways are similarly 
affected in wild-type vs. shATG5 mice. 
 
Moreover, there are reports out there, saying that Dox may induce mitophagy (Xing-Y et al., Front 
Cell Infect Biol 2017), hence, the effects reported might be further specifically or non-specifically 
altered by autophagy-related drug effects, among them the suppression of cancer stem cell 
characteristics (Zhang-L et al., Cell Cycle 2017), which may contribute to the reversal of the liver 
and kidney dysfunctionalities (i.e. just Dox- and shAtg5-aggravated organ toxicities?) and boosted 
tumor incidence detected upon its withdrawal. 
 
2. What is the nature of the widespread immune infiltrates (innate, adaptive?) as presented in 
Suppl. Fig. 3a? Is there evidence for autoimmune tissue damage, e.g. vasculitis? Do the LT-Atg5i 
mice present with higher titer autoantibodies? And how relevant is the target tissue (kidney, heart, 
muscle a.o.) as compared to the autophagy inhibition in hematopoietic/immune cells? Can similar 
phenotypes, even shortened lifespan due to accelerated aging, be observed in wild-type recipient 
mice being reconstituted with LT-ATG5i hematopoietic stem cells? And, upon Dox withdrawal, 
would those mice develop tumors others than AML and lymphoma? 
 
3. There seem to be some controversial findings: autophagy inhibition has been shown (actually 
by the authors themselves) to prevent senescence (Young-AR et al., Genes Dev 2009), as 
autophagy inhibition in senescence results in secondary cell death (Dörr-JR et al., Nature 2013), 
mTOR inhibition (promoting autophagy) extends lifespan (Harrison-DE et al., Nature 2009) and, at 
least in some settings, enforces senescence (Wall-M et al., Cancer Discovery 2012), albeit lowering 
the senescence-associated secretory phenotype (SASP) implicated in chronic inflammaging 
(Laberge-RM et al., Nat Cell Biol 2015; Herranz-N et al., Nat Cell Biol 2015), and continuous 
removal of senescent cells in a whole mammalian organism exerting a rejuvenation phenotype 
with reduced age-related organ pathologies (Baker-D et al., Nature 2011 and 2016), while 
senescence more recently was associated with cell-autonomous and non-cell-autonomous 
reprogramming into stemness (Mosteiro-L et al., Science 2016; Milanovic-M et al., Nature 2018), 
as opposed by the claim of autophagy maintaining stemness by preventing senescence (Garcia-
Prat-L et al., Nature 2016). 
 
Although it’s only fair to look at the findings as they were obtained in the specific test system 
presented here, there is room for misinterpretation if interconnected mechanisms are not 
considered. Specifically: why is it necessarily “autophagy restoration” that accounts for the partial 
reversal of the premature aging phenotypes induced by Dox treatment before? What is the fate of 
shAtg5-related senescent cells: do they re-enter the cycle and divide again, or do they – upon 
“Atg5 restoration stress” – rather die, thereby mimicking an aging scenario, in which senescent 
cells are senolytically removed, as previously reported with the result of organismic rejuvenation 
and reduced age-related organ pathologies in an INK4a-driven senolysis transgenic mouse model 
(Baker-D et al., Nature 2011 and 2016)? However, the persistence of telomere-associated foci as a 
marker of senescent cells would argue against this view – if the comparison would just be more 
clear in this regard: in Fig. 4B (and following figure panels, except 4C), where is the comparison 
LT-Atg5i at the end of 4-mon Dox vs. two months of no Dox exposure later? 
 
4. In part already addressed under “1.”, it remains unclear whether only extracellular matrix-
related alterations (such as osteopenia/kyphosis, or cardiac fibrosis) did not revert upon Dox 
removal due to their structural nature, or actually none of the premature aging-like phenotypes 
was reversed, and all improvement observed is due to lifted chronic toxicity that was exerted by 
Dox in the absence of Atg5. 
 
5. Are there any characteristic biological or genetic patterns shared by the tumors emerging upon 
Dox withdrawal in R-Atg5i mice? For example, do they consistently present with an autophagy 
defect, irrespective of the interrupted Dox exposure? Or do they exhibit an inability to undergo 
senescence, and/or are typically driven by Ras/Braf/Mek-type oncogenes? Or is their hallmark 
defect massive genomic instability or aneuploidy? Unfortunately, there is virtually nothing shown in 
this regard. 
 
6. Did the authors test the effect of an inducible Atg5 allele on top of a normal Atg5 gene dose at 





1. In Suppl. Fig. 2e, the authors report Congo red-positive (and birefringent?) staining of amyloid 
in the kidney. Is this precipitation selectively found in the glomerulus or also elsewhere throughout 
the body (e.g. subcutaneous fat, rectum mucosa)? What type of amyloid is it (AA, AL, or the senile 
type AS)? The precursor amyloid and the underlying mechanism – lack of autophagic processing of 
the precursor protein or indirect promotion of chronic inflammation, infection, or clonal plasma cell 





Remarks to the Author: 
In this study, Dr. Narita’s groups formulates the question as to whether decrease in autophagy 
contributes to aging and whether this effect of autophagy in aging can be reverted. They have 
used inducible models of Atg5 deletion, a gene required for some autophagic processes, and show 
tha deletion of Atg5 in young adult mice leads to aging phenotypes, and that restoration of the 
gene improvs healthspan but cannot prevent the increase in spontaneous carcinogenesis. 
This is an interesting and important question to address, since animals with constitutive induction 
of autophagy since birth have shown extension of life and health-span and lower incidence of 
tumors. However, an anti-aging intervention that needs to start at birth it is unlikely to be 
implemented. Since the most likely scenario is going to be attempts to upregulate autophagy in 
adult middle age individuals, this warning about the inability to prevent carcinogenesis through 
this intervention is important. 
Overall the study is well designed and the conclusions supported, but considering that the mice die 
by about 6 months of age, there is some concern about who much this is really aging versus 
overall health conditions. Furthermore, since the phenotype that cannot be restored is mostly 
related with senescence, one wonders how much this is a model of aging versus a model of 
accelerated senesnce. A later intervention (i.e. by 12 months) would have been more 
informative/related to aging. The other major limitation is that they authors do not present any 
information about autophagy. Considering the growing number of non-autophagy functions 
attributable to ATG genes and the already known function of Atg5 in cell death, it would be 
essential that they characterize the status of the autophagic system across organs. 
Main points 
 
- Repetition of some of the induction and restoration experiments at a later age (12 months) 
would strengthen the conclusions in relation with aging. 
- Characterization of the status of the autophagic system and evidence of absence of autophagic 
activity needs to be presented. The only data in the whole manuscript is a reduction in LC3-II 
levels but considering previous reports where even in the ATG5 KO mice presence of autophagic 
vacuoles has been observed, they should include electron microscopy to determine whether or not 
there are autophagy vacuoles and measure of flux (degradation) of some typical autophagic cargo. 
- Better characterization of the penetrance of the KD in different tissues should be presented. KD 
information is only shown for liver, heart and kidney. This data is also missing in the second 
hairpin studies what makes difficult to support the claims for hypomorphic reduction in Atg 5. 
- In the restoration experiments, for the biochemical parameters it is very difficult to get an idea of 
the recovery because comparisons are done only with control (if I understand correctly in Fig. 4b 
the blots “R-Ctr” represent control mice but it would be important to compare with the group KD 
non restored too and ideally show the status of the restored also right before dox is added again. 
Comparing those 4 groups (or the nice time course that they did for example in the frailty studies) 
will be very important to understand better the surprising cancer phenotype. 
Other comments: 
- comments on mitochondria function/status need to be supported by functional data or soften as 
the authors only show levels of TOM and that is insufficient to support any functional claim 






Remarks to the Author: 
In this manuscript, Cassidy and collaborators undertake a detailed characterization of their 
recently generated mouse models that allow inhibition of autophagy and its reinduction, at wish. 
Using lines for dox-inducible shRNA for Atg5, the authors demonstrate that blocking autophagy in 
adult mice drives several phenotypes associated to premature aging and reduced longevity, being 
some of them alleviated by restoration of autophagy. Importantly, the study shows that 
autophagy-restored mice develop tumors more frequently and earlier that autophagy-inhibited 
mice alone. These results are of interest to the autophagy and aging communities as autophagy 
has not been precisely confirmed as causal of aging-associated tissue/organ dysfunction; neither 
has its reinduction been confirmed as causally involved in reversal of aging. However, several 




- The authors should discuss whether premature aging in this mouse model is provoked by specific 
inhibition of autophagy by a multi-organ failure (provoked by inhibition of autophagy -for example, 
by hepatic failure) which in turn accelerates aging. This discussion should not be a show-stopper. 
It would just be appreciated if the authors clarify a bit more their major claims. 
 
- Figure 2. Adult control mice (mice with normal autophagy) show some central nucleated fibers in 
skeletal muscle in resting state. This is not usually observed at this age. Authors should revise 
these data or provide a potential explanation. Some fibers in control mice are really big (bigger 
than normal fibers). Authors should make sure that the measurements correspond to cross-
sectional areas of muscle biopsies (and not muscles cut a bit longitudinally). 
 
- Figure 3. Is p16 expression also elevated in tissues other than liver? Telomere shortening seems 
quite elevated in control adult mice. Telomere/DNA damage analysis would be informative also for 
other tissues/organs. 
 
- Figure 4. Could statistics be described a bit further? Could the authors also indicate more 
precisely and with more detail the frailty parameters that they measured? Control mice of 8 
months of age seem somehow too frail for this adult age. Therefore, better understanding of this 
methodology will help in understanding the results of this figure. 
 
- Figure 5. Muscle-related data of this figure is not matching always with similar data shown in 
Figure 2. A bit of revision will help. 
 
- Supplem. Figure 6. Weights of all mouse models (prior/after dox treatment/removal) should be 
shown in this figure or elsewhere. 
Reviewers' comments and point-by-point responses 
 
Reviewer #1 (Remarks to the Author): 
Cassidy-LD,... …Narita-M, Temporal inhibition of autophagy reveals segmental reversal of aging with 
increased cancer risk 
 
Submitted to Nature Communications 
 
In this manuscript, Narita and colleagues investigate the link between autophagy inhibition and 
premature aging (following up, from an opposite entry point, on previous work in the field on mTOR 
inhibition, leading to enhanced autophagy), and its association with prolonged lifespan. Conversely, 
the authors find restoration of autophagy to result in partial recovery of age-associated phenotypes, 
but being associated with an increased rate of tumor formation. The authors conclude that the 
preceding inhibition of autophagy determined the elevated cancer risk (but did not test whether 
hyperactivation of autophagy from normal baseline level would also result in higher cancer incidence).  
 
While the concept of this manuscript is not entirely novel, it provides – based on an elegant technical 
approach – important insights into autophagy-related aging mechanisms, their therapeutic 
implications (although one would have liked to see pharmacological data using Bafilomycin, 
Rapamycin and AMPK modulators to match and validate a purely gene-engineered model system in a 
more translational fashion) and surprising effects in terms of tumorigenesis. However, several 
fundamental concerns and specific questions remain before publication in Nature Communications 
should be considered. 
 
General response to reviewer: we are grateful for the general feedback and specific recommendations 
by the reviewer. In particular, we believe the reviewer’s suggestions to further characterise the 
autonomous vs non-autonomous nature of the immune phenotypes has significantly improved the 
manuscript. The results of this will almost certainly generate an exciting new strand of research within 
the lab, and strengthen existing collaborations. Point-by-point responses to the reviewer’s comments 
can be found below. 
 
Major concerns and comments 
 
1. Potentially, the entire investigation might be flawed by a direct interference of the autophagic 
process with the drug metabolism of Doxycycline, either directly (ribosomal binding) or via an indirect 
metabolizing process (e.g. glucuronidation). Since no alternatively inducible shATG5 allele can be 
generated within reasonable time and effort, the authors need to provide evidence that steady-
state/trough serum levels of Dox and typical direct Dox target pathways are similarly affected in wild-
type vs. shATG5 mice.  
 
Moreover, there are reports out there, saying that Dox may induce mitophagy (Xing-Y et al., Front Cell 
Infect Biol 2017), hence, the effects reported might be further specifically or non-specifically altered 
by autophagy-related drug effects, among them the suppression of cancer stem cell characteristics 
(Zhang-L et al., Cell Cycle 2017), which may contribute to the reversal of the liver and kidney 
dysfunctionalities (i.e. just Dox- and shAtg5-aggravated organ toxicities?) and boosted tumor 
incidence detected upon its withdrawal. 
 
We have attempted to address the reviewers concern here in two ways. Firstly, as suggested we took 
serum doxycycline levels from control and experimental cohorts and measured their serum steady-
state levels after 4 months of treatment. We found no difference between the mice based on 
genotype and the values are comparable to those previously published [PMID 27423155]. These data 
can now been seen in new Supplementary Figure 1d. Of note, in this study, we used a low dose 
regimen of dox (200PPM) whilst in comparison many labs use 625PPM, often results in serum levels 
up to 10X times higher than our mice display. We are able to do this due to the high sensitivity afforded 
by the Cags-rtTA3 system. However, we accept that it is impossible to rule out synergistic effects of 
the dox and autophagy inhibition (as it would equally be for other widely used inducible model 
systems i.e. tamoxifen). As such we have also added this as a discussion point (3rd paragraph of the 
discussion) to highlight what is undoubtedly an important caveat, and one that to our knowledge has 
never been rigorously addressed in similar genetically engineered inducible mouse model systems.  
 
2. What is the nature of the widespread immune infiltrates (innate, adaptive?) as presented in Suppl. 
Fig. 3a?  
Is there evidence for autoimmune tissue damage, e.g. vasculitis? Do the LT-Atg5i mice present with 
higher titer autoantibodies?  
And how relevant is the target tissue (kidney, heart, muscle a.o.) as compared to the autophagy 
inhibition in hematopoietic/immune cells? 
Can similar phenotypes, even shortened lifespan due to accelerated aging, be observed in wild-type 
recipient mice being reconstituted with LT-ATG5i hematopoietic stem cells?  
And, upon Dox withdrawal, would those mice develop tumors others than AML and lymphoma? 
 
The reviewer raises a number of very interesting questions and we have attempted to address as much 
as possible here. Firstly, representative staining and quantification for immune infiltrations in various 
tissues can be seen in new Supplementary Figure 5b-d.    
 
In terms of autoimmunity, we have not seen any reproducible evidence of vasculitis via analysis with 
a pathologist. However, as suggested by the reviewer, we have also performed an Antinuclear 
Antibody Test to determine if there is any evidence of autoimmunity in the Atg5i mice. The results can 
be found in new Supplemental Figure 5e and suggest that there is an increase in the frequency of 
autoimmunity in the Atg5i mice. A positive signal was determined to be present in 5/12 (41.7%) Atg5i 
mice in comparison to 1/6 (16.7%) of age matched control mice, with the predominant pattern 
homogenous and/or speckled. Of note, while autoimmunity was only positive in 5/12 Atg5i mice, 
immune expansion and infiltration is a universal phenotype.  
 
We agree with the reviewer that the relevance of the immune system autophagy loss versus the tissue 
autophagy loss is of great interest. As such we have performed the bone marrow transplant (BMT) 
experiment as suggested. To do this, we took Control and Atg5i mice that had recently been 
backcrossed 11 times to C57/BL6, and reconstituted 5 lethally irradiated wild-type C57/BL6 mice per 
genotype (N= 5 Ctrl and 5 Atg5i). After 1 month, these mice were treated with doxycycline and at 4 
months blood was taken for analysis. The results are interesting. Previously, we noted an expansion 
of the myeloid lineage and increased cellularity of the peripheral immune system in Atg5i mice. 
However, in our wild-type mice with Atg5i bone marrow, we only saw a myeloid skewing (new Fig. 
2e), but this did not coincide with an expansion of cellularity (peripheral white blood cell count, new 
Fig. 2b), thus providing a separation of immune phenotypes. This suggests that the loss of autophagy 
in the immune cells produces a myeloid bias (cell-autonomous effect), whilst loss of autophagy in non-
immune cells stimulates their expansion (non-cell-autonomous effect). Furthermore, PCR based 
analysis suggests that bone marrow from Atg5i mice actually constituted a lower fraction of the 
peripheral blood.  
 
Upon closer inspection, our results are highly consistent with the published literature. To place this 
experiment in context, an analogous experiment was performed by the lab of Emmanuelle Passegue 
(PMID 28241143). Here the authors knocked-out a key autophagy gene (Atg12) in the immune system 
using the Mx1-Cre model (using pIC to induce recombination), and note an expansion of the immune 
system and a myeloid skewing, an effect recapitulated in our Atg5i mice. Next, they transplanted bone 
marrow from Atg12flox/flox mice (not yet treated with pIC and as such autophagy competent) into wild-
type hosts and left them 2 months to enable reconstitution. After treatment with pIC, which induced 
deletion of Atg12, instead of an expansion of the peripheral immune system, the authors note a 
gradual reduction in chimerism, but these mice still recapitulated the myeloid skewing. As such the 
data are in agreement with our new Atg5i-BMT data. It is important to note that, the Mx1-Cre model 
used by Passegue and colleagues, also induces liver recombination, as such they do not use a pure 
immunological system and we would speculate that their immune expansion may be in-part, driven 
by the resultant liver autophagy loss.  
 
FInally, while we fully agree that expanding these BMT experiments as well as performing longevity 
and tumour studies would be of great interest, these are large studies spanning three to five years. 
We have however performed frailty scoring of mice with BMT uncovered no evidence of accelerated 
ageing (new Supplementary Figure 5f). 
 
We would like to reiterate that these were excellent points raised by the reviewer and we thank them 
for their suggestion. These results are undoubtedly very interesting and will form the basis of new 
avenues of work. 
 
3. There seem to be some controversial findings: autophagy inhibition has been shown (actually by 
the authors themselves) to prevent senescence (Young-AR et al., Genes Dev 2009), as autophagy 
inhibition in senescence results in secondary cell death (Dörr-JR et al., Nature 2013), mTOR inhibition 
(promoting autophagy) extends lifespan (Harrison-DE et al., Nature 2009) and, at least in some 
settings, enforces senescence (Wall-M et al., Cancer Discovery 2012), albeit lowering the senescence-
associated secretory phenotype (SASP) implicated in chronic inflammaging (Laberge-RM et al., Nat 
Cell Biol 2015; Herranz-N et al., Nat Cell Biol 2015), and continuous removal of senescent cells in a 
whole mammalian organism exerting a rejuvenation phenotype with reduced age-related organ 
pathologies (Baker-D et al., Nature 2011 and 2016), while senescence more recently was associated 
with cell-autonomous and non-cell-autonomous reprogramming into stemness (Mosteiro-L et al., 
Science 2016; Milanovic-M et al., Nature 2018), as opposed by the claim of autophagy maintaining 
stemness by preventing senescence (Garcia-Prat-L et al., Nature 2016). 
 
Although it’s only fair to look at the findings as they were obtained in the specific test system 
presented here, there is room for misinterpretation if interconnected mechanisms are not considered. 
Specifically: why is it necessarily “autophagy restoration” that accounts for the partial reversal of the 
premature aging phenotypes induced by Dox treatment before? What is the fate of shAtg5-related 
senescent cells: do they re-enter the cycle and divide again, or do they – upon “Atg5 restoration stress” 
– rather die, thereby mimicking an aging scenario, in which senescent cells are senolytically removed, 
as previously reported with the result of organismic rejuvenation and reduced age-related organ 
pathologies in an INK4a-driven senolysis transgenic mouse model (Baker-D et al., Nature 2011 and 
2016)? However, the persistence of telomere-associated foci as a marker of senescent cells would 
argue against this view – if the comparison would just be more clear in this 
regard: in Fig. 4B (and following figure panels, except 4C), where is the comparison LT-Atg5i at the end 
of 4-mon Dox vs. two months of no Dox exposure later? 
 
It is true that the relationship between autophagy and senescence is complex and highly context 
dependent. It is important to note that both basal autophagy and stress-induced autophagy are 
relevant for senescence. We have shown that stress- (genotoxic and oncogenic) induced autophagy 
contributes the inflammatory SASP, although its impact on senescence ‘arrest’ is marginal. In contrast, 
it is known that basal autophagy is critical for cellular fitness thus depletion of basal autophagy would 
promote senescence. In addition, increasing evidence indicates that autophagy has multiple action 
points in senescence effectors (the SASP, cGAS-STNG etc.). We have extensively discussed this point 
in our recent review article in Genes & Dev (PMID 30709901).  
 
As suggested by the reviewer, we have now included new data for the comparison of mice at 4 months 
and 4 months post dox removal in new Figure 4b. In the liver, we find that p16 levels (whilst elevated 
in comparison to controls in the restored cohorts) are lower than in the cohorts with autophagy 
inhibited. Interestingly, the kidney displays only a modest increase in p16 during autophagy inhibition, 
and is completely recovered in the resorted cohorts; suggestive of differential tissue susceptibility to 
autophagy inhibition. We agree that this is an important comparison for relative data (such as western 
blots) as it enables the direct comparison with the 4 month-timepoint for the senescent and 
autophagy markers. While how the (partial) reduction of senescence load was achieved (either 
senescence escape, cell death, or immune elimination), it is possible that the reduced senesce-load 
might contribute to the partial age-reverse upon autophagy restoration. However, this is too 
speculative and we did not mention this possibility in discussion. This is a fundamental question that 
we hope to address in the future. 
 
The corresponding 4-month data for white blood cell counts (old Figure 4d) and serum cytokine levels 
(old Figure 4e), can be seen in Figure 2b and 2d, respectively. For the 4 month RDW values we have 
now included these in the manuscript (Figure 4f). Briefly, there is no RDW differences at the 4-month 
timepoint and, whilst there appears an age-related increase at the 12 months, a further increase can 
be seen in the R-Atg5i cohorts in comparison to the R-Ctrl. We thank the reviewer for the suggestion 
to include these data. 
 
 
4. In part already addressed under “1.”, it remains unclear whether only extracellular matrix-related 
alterations (such as osteopenia/kyphosis, or cardiac fibrosis) did not revert upon Dox removal due to 
their structural nature, or actually none of the premature aging-like phenotypes was reversed, and all 
improvement observed is due to lifted chronic toxicity that was exerted by Dox in the absence of Atg5. 
Please see “1” 
 
5. Are there any characteristic biological or genetic patterns shared by the tumors emerging upon Dox 
withdrawal in R-Atg5i mice? For example, do they consistently present with an autophagy defect, 
irrespective of the interrupted Dox exposure? Or do they exhibit an inability to undergo senescence, 
and/or are typically driven by Ras/Braf/Mek-type oncogenes? Or is their hallmark defect massive 
genomic instability or aneuploidy? Unfortunately, there is virtually nothing shown in this regard.  
 
The reviewer raises many excellent questions here. We agree that addressing the role of autophagy 
in these tumours is an important and performed IHC for p62 (a marker associated with a block in 
autophagy). An example can be seen in Figure 6d. We have seen no evidence that autophagy 
continues to be inhibited in the tumours from R-Atg5i mice and have added a line to the last paragraph 
in the results section to convey this message. Further, systematic characterisation of tumours is 
currently ongoing, particularly focusing on genome-sequence approaches. We emphasise that our 
mice do not just model premature ageing but also age-associated spontaneous tumorigenesis. As 
implied by the reviewer, it is conceivable that genomic instability that might have been induced by 
autophagy defect, could increase the cancer risk, which causes cancer development only in the 
autophagy proficient condition. Our model raises a possibility that we might even be able to observe 
(epi)genomic events that precede cancer development. We are actively working on this fundamental 
question. 
 
6. Did the authors test the effect of an inducible Atg5 allele on top of a normal Atg5 gene dose at 
earlier or later (aging-related) time points? 
 
Unfortunately, we did not develop a mouse with an inducible Atg5 allele. However, a GEMM study 
has been published wherein Atg5 is constitutively overexpressed from embryogenesis (PMID: 
23939249) and recently another paper was published describing a GEMM with constitutively high 
basal autophagy flux (PMID:29849149). Both studies argue that increased autophagy leads to an 
extension of health and life-span. Both of these studies were cited in the original manuscript 
(introduction and discussion) as they are complementary to our data. Their data combined with ours 
suggest that maintaining a high basal autophagic flux can help prevent damage that normally 
accumulates with age, however our data additionally provide evidence that 1) reduction of autophagy 
(in adults) promotes ageing, 2) such ageing is partially reversible, and 3) autophagy decline is not 
sufficient for tumorigenesis but increases a cancer risk.  
 
We argue this knowledge is essential as the therapeutic promotion of autophagy in the general 
population would not occur from birth, it would instead occur later in life. Perhaps after irreversible 





1. In Suppl. Fig. 2e, the authors report Congo red-positive (and birefringent?) staining of amyloid in 
the kidney. Is this precipitation selectively found in the glomerulus or also elsewhere throughout the 
body (e.g. subcutaneous fat, rectum mucosa)? What type of amyloid is it (AA, AL, or the senile type 
AS)? The precursor amyloid and the underlying mechanism – lack of autophagic processing of the 
precursor protein or indirect promotion of chronic inflammation, infection, or clonal plasma cell 
expansion/monoclonal gammopathy leading to amyloid formation – should be addressed. 
 
As this data was ancillary we have removed this data and discussion points. The reviewer quite rightly 
points out this is fairly preliminary and we believe a more significant, independent study would be 
required beyond our current capacity.  
 
 
Reviewer #2 (Remarks to the Author): 
In this study, Dr. Narita’s groups formulates the question as to whether decrease in autophagy 
contributes to aging and whether this effect of autophagy in aging can be reverted. They have used 
inducible models of Atg5 deletion, a gene required for some autophagic processes, and show tha 
deletion of Atg5 in young adult mice leads to aging phenotypes, and that restoration of the gene 
improvs healthspan but cannot prevent the increase in spontaneous carcinogenesis. 
This is an interesting and important question to address, since animals with constitutive induction of 
autophagy since birth have shown extension of life and health-span and lower incidence of tumors. 
However, an anti-aging intervention that needs to start at birth it is unlikely to be implemented. Since 
the most likely scenario is going to be attempts to upregulate autophagy in adult middle age 
individuals, this warning about the inability to prevent carcinogenesis through this intervention is 
important. 
Overall the study is well designed and the conclusions supported, but considering that the mice die by 
about 6 months of age, there is some concern about who much this is really aging versus overall health 
conditions. Furthermore, since the phenotype that cannot be restored is mostly related with 
senescence, one wonders how much this is a model of aging versus a model of accelerated senesnce. 
A later intervention (i.e. by 12 months) would have been more informative/related to aging. The other 
major limitation is that they authors do not present any information about autophagy. Considering 
the growing number of non-autophagy functions attributable to ATG genes and the already known 
function of Atg5 in cell death, it would be essential that they characterize the status of the autophagic 
system across organs. 
 
General response to reviewer: We appreciate the constructive and positive comments from the 
reviewer regarding both the design and importance of the work. We have now provided substantially 
more evidence to the manuscript, including EM, an in vivo autophagy flux assay, and additional 
staining across various tissues to reinforce the loss of autophagy across multiple organs. This 
combined with our technical paper describing the model in Autophagy (PMID 29999454) provides 
strong supportive evidence of autophagy perturbation across the majority of tissues. A point-by-point 




- Repetition of some of the induction and restoration experiments at a later age (12 months) would 
strengthen the conclusions in relation with aging. 
Whilst performing the experiments in older cohorts would provide an interesting comparison (as we 
predict phenotypes may become more pronounced and recovery would be less robust) we do not 
believe they are necessary in this instance to support the notion that Atg5i mice have accelerated 
ageing, as we expect the phenotypes to be broadly similar. 
 
- Characterization of the status of the autophagic system and evidence of absence of autophagic 
activity needs to be presented. The only data in the whole manuscript is a reduction in LC3-II levels 
but considering previous reports where even in the ATG5 KO mice presence of autophagic vacuoles 
has been observed, they should include electron microscopy to determine whether or not there are 
autophagy vacuoles and measure of flux (degradation) of some typical autophagic cargo. 
 
To address the reviewer’s comments, we have performed EM on liver tissue from Atg5i and control 
mice that have been treated with doxycycline for 6 weeks. Of note, we can see the appearance of 
stacked and vacuolated membranes that one would expect to see upon autophagy inhibition. This 
data is now included in new Supplementary Figure 1a. 
 
Additionally, we have performed an in vivo flux experiment wherein mice had autophagy inhibited for 
3 weeks before dox was removed and a time-course was followed to watch the re-establishment of 
autophagy with the subsequent removal of typical autophagic cargo that had built up over time (new 
Supplementary Figure 1b and c). Note, the timing of Atg5 recovery and reduction of accumulated 
cargos (p62, NBR1) are well correlated: the former slightly precedes the latter, adding further evidence 
to support Atg5 and autophagy were inhibited.  
 
We would also like to re-iterate that while these mice have reduced autophagy (phenotypically 
supported through p62/Sqstm1, LC3-I build-up, and by EM), as it is fundamentally a knockdown 
experiment (more physiological than KO experiments), we do not preclude the possibility that some 
autophagosome biogenesis is occurring and that flux through the autophagy pathway may be present. 
We have furthermore added a line to the second paragraph of the discussion as this is a point of 
central importance, particularly when comparing this model to the knockout models. We thank the 
reviewer for highlighting this and believe the discussion is now more comprehensive in this regard. 
 
- Better characterization of the penetrance of the KD in different tissues should be presented. KD 
information is only shown for liver, heart and kidney. This data is also missing in the second hairpin 
studies what makes difficult to support the claims for hypomorphic reduction in Atg5. 
 
In 2018, we published a technical paper (PMID 29999454) extensively describing the mouse model 
and including the penetrance of the knockdown across a broad range of tissues which included 
pancreas, spleen, skeletal muscle, liver, lung, heart, seminal vesicles and brain, as well as using MEFs 
in in vitro experiments. To further validate the model, we have now included example images of 
Sqstm1/p62 accumulation across several tissues (spleen, lung, salivary gland, pancreas, skeletal 
muscle, heart) in new Supplementary Figure 2a, in addition to those data already present (Figure 3, 4, 
5 and Supplementary Figure 6).  
 
We have also added new heart and lung IHC for Sqstm1/p62 and LC3 for the Atg5i_2 mouse model in 
new Supplementary Figure 7f. Additionally, the hypomorphic nature of the second hairpin mouse is 
based on three findings. The first is that they do not display some of the key phenotypes associated 
Atg5 KO, the first hairpin mouse does. The second is that the mice do not display as strong a level of 
p62 build-up or diffuse LC3 build up. The third is that the mice display similar ageing phenotypes but 
at a reduced rate. We chose the second shRNA sequence from our initial screening, in which this 
exhibited the second highest efficiency of KD, shAtg5 #3 (Atg5_1654) in our paper (PMID 29999454), 
the best one was used for the first Atg5i mouse. Additionally, we have now included better description 
of the second shRNA in the methods section. Nevertheless, both hairpins display a highly efficient KD 
via western blot analysis, and that the difference between the two hairpins is very low. However, it is 
known that inhibiting Atg5 dependent autophagy requires a very high KD efficiency (PMID 16647067), 
explaining that such a small difference in the Atg5 level results in substantial phenotypical differences. 
 
- In the restoration experiments, for the biochemical parameters it is very difficult to get an idea of 
the recovery because comparisons are done only with control (if I understand correctly in Fig. 4b the 
blots “R-Ctr” represent control mice but it would be important to compare with the group KD non-
restored too and ideally show the status of the restored also right before dox is added again. 
Comparing those 4 groups (or the nice time course that they did for example in the frailty studies) will 
be very important to understand better the surprising cancer phenotype. 
 
We thank the reviewer for this suggestion, we agree that comparing to the 4-month timepoint in the 
same blot is highly informative. We have now updated this figure as suggested and it is possible to see 
the restoration of Atg5 and LC3 (-I and -II) to similar basal levels for Liver and kidney tissue (new Fig 
4b). Of note this result also highlights how senescence markers alter over time in different tissues. 
Consistent with telomere-associated γ-H2AX foci (TAF) data, in liver p16 levels remained high in R-
Atg5i (compared to littermate controls), although this is not as prominent as in the LT-Atg5i mice (4-
months dox), suggesting incomplete recovery after autophagy restoration. Meanwhile in the kidney, 
p16 exhibits only modest increase while autophagy is inhibited, and this appears to fully recover 4 
months after dox removal. 
  
Other comments: 
- comments on mitochondria function/status need to be supported by functional data or soften as the 
authors only show levels of TOM and that is insufficient to support any functional claim 
 
As correctly pointed out by the reviewer, we have not performed any functional work, as such we 
have altered our text to reflect this. 
 
 
- It would be desirable including some images of the muscle as done for other tissues 
We have now added images of the muscle, both in regards to p62 and LC3 in new supplementary 
figure 2, as well as example images for our morphometry analysis in Supplementary Figure 6a 
 
 
Reviewer #3 (Remarks to the Author): 
In this manuscript, Cassidy and collaborators undertake a detailed characterization of their recently 
generated mouse models that allow inhibition of autophagy and its reinduction, at wish. Using lines 
for dox-inducible shRNA for Atg5, the authors demonstrate that blocking autophagy in adult mice 
drives several phenotypes associated to premature aging and reduced longevity, being some of them 
alleviated by restoration of autophagy. Importantly, the study shows that autophagy-restored mice 
develop tumors more frequently and earlier that autophagy-inhibited mice alone. These results are of 
interest to the autophagy and aging communities as autophagy has not been precisely confirmed as 
causal of aging-associated tissue/organ dysfunction; neither has its reinduction been confirmed as 
causally involved in reversal of aging. However, several issues need further experimental evidences to 
strengthen their conclusions. 
General response to reviewer: We thank the reviewer not only for their positive comments regarding 
the importance of the work, and the subsequent interest to the community, but also for his/her 
constructive comments on the muscle related datasets. We have now re-isolated and performed all 
the assays with particular care taken in the isolation, fixation, cutting depth, and image analysis for all 
the samples. As such we now believe the muscle dataset is far more robust than before. In addition, 
we have also added a new dataset (4 months on dox) to the manuscript. Point-by-point responses to 




- The authors should discuss whether premature aging in this mouse model is provoked by specific 
inhibition of autophagy by a multi-organ failure (provoked by inhibition of autophagy -for example, by 
hepatic failure) which in turn accelerates aging. This discussion should not be a show-stopper. It would 
just be appreciated if the authors clarify a bit more their major claims. 
The reviewer raises a very important discussion point that we agree should be expanded upon further. 
While it is possible that organ damage might contribute to the accelerated ageing phenotypes, the 
premature ageing phenotypes of our mice are not driven specifically by these organ damages (e.g. the 
hepatomegaly phenotypes), as these are absent from LT-Atg5i_2 mice. This point has been reinforced 
in the Discussion.  
 
- Figure 2. Adult control mice (mice with normal autophagy) show some central nucleated fibers in 
skeletal muscle in resting state. This is not usually observed at this age. Authors should revise these 
data or provide a potential explanation. Some fibers in control mice are really big (bigger than normal 
fibers). Authors should make sure that the measurements correspond to cross-sectional areas of 
muscle biopsies (and not muscles cut a bit longitudinally). 
 
- Figure 5. Muscle-related data of this figure is not matching always with similar data shown in Figure 
2. A bit of revision will help. 
 
We thank the reviewer for their suggestions here. To address these two issues (Figure 2 and Figure 5), 
we re-isolated tissues from mice with particular care taken with the snap freezing technique and 
subsequent sectioning. In addition, in all tissues we sectioned 1/3 into the tissue in an attempt to get 
a similar depth for analysis.  For all analysis, we next manually removed all fibres that appeared to be 
cut longitudinally in a blinded fashion. Due to this we believe the data are now far more robust and 
comparable. 
 
- Figure 3. Is p16 expression also elevated in tissues other than liver? Telomere shortening seems quite 
elevated in control adult mice. Telomere/DNA damage analysis would be informative also for other 
tissues/organs. 
 
We also showed western blotting for p16 in the muscle in the original version (now in new 
Supplementary Figure 6c). We have now performed p16 western blotting for kidneys (new Figure 4b), 
in addition to expanding our TAF counting to lung and heart also which displayed the same general 
trend as in the liver (new Supplemental Figure 6d and e).  
 
For the TAF analysis, the numbers are similar to those previously reported by Hewitt et al. (PMID 
22426229, Figure 5). Importantly we should add that TAF do not necessarily represent shortened 
telomeres, a concept described and discussed in this original paper, just DNA damage at telomeres 
(mostly irreparable). We have added a line into to emphasise this for clarification. 
 
- Figure 4. Could statistics be described a bit further? Could the authors also indicate more precisely 
and with more detail the frailty parameters that they measured? Control mice of 8 months of age 
seem somehow too frail for this adult age. Therefore, better understanding of this methodology will 
help in understanding the results of this figure. 
 
We have expanded this section in the methods and fully agree with the reviewer that more detailed 
information would be beneficial, especially considering a number of frailty scoring systems exist in the 
literature. This can now be seen in the updated methods section of the manuscript. Our scores are 
similar both to the original published paper, and an independently scored aged cohort at a different 
location (University of Newcastle, E. Fielder, personal communication). As the frailty score is in 
essence a qualitative score, it is open to differences in the scoring between individuals and research 
groups. To reduce variability and correctly score these qualitative metrics we believe it is essential 
therefore to use the same researchers to measure the same mice (in a blinded fashion), as we have 
done in this instance, as this provides a degree of internal control.   
 
- Supplem. Figure 6. Weights of all mouse models (prior/after dox treatment/removal) should be 
shown in this figure or elsewhere. 
 









Remarks to the Author: 
Cassidy-LD,... …Narita-M, Temporal inhibition of autophagy reveals segmental reversal of aging 
with increased cancer risk 
 
Submitted to Nature Communications 
 
 
This is now a substantial revision of the scientifically very interesting manuscript on the link 
between autophagy inhibition and premature aging with a specific focus on autophagy restoration 
that led to partial recovery of age-associated phenotypes, but an increased rate of tumor 
formation. Despite an important extension of previous work in the field and the elegant 
investigation of a very useful conditional ATG5 mouse model, the initially submitted version raised 
a number of fundamental concerns and specific questions. 
 
Being aware of the many global and detailed aspects I pointed out in my statement, I would like to 
thank the authors for an unusually careful and comprehensive discussion of the critique, and the 
significant additional experimental work now provided in the re-submission. Although not all 
concerns were addressed (with some of them, I admit, hard-to-impossible to solve in reasonable 
time with reasonable efforts), I have no further objections. The current manuscript is now much 










-Repetition of some of the induction and restoration experiments at a later age (12 months) would 
strengthen the conclusions in relation with aging. 
 
I agree with the authors that doing these new experiments (at 12 months of age) would be 
informative; yet, it is clear that Atg5i mice are a new model of accelerated aging, and at this point 




-Characterization of the status of the autophagic system and evidence of absence of autophagic 
activity needs to be presented. 
 
The authors present sufficient new data on autophagy analysis (EM, flux assays, p62/Sqstm1,LC3-
I build-up). 
 
- Better characterization of the penetrance of the KD in different tissues should be presented. 
 
The authors already showed data related to KD penetrance in a previous paper, and in the present 




- Restoration/recovery experiments. 
 
The figure is now updated and the restoration of Atg5 and LC3 to similar basal levels for liver and 




Minor points are well addressed. 
 
 
In sum, I think that the authors have addressed well the major concerns of Reviewer 2. 
